ArticleCVIR endovascular2026
Cerebral DWI lesion burden following carotid artery stenting with guided antiplatelet therapy: a retrospective comparative study.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo analyze the number, location, and clinical significance of new ischemic lesions (NIL) after carotid stenting in patients with guided antiplatelet therapy. To evaluate factors leading to thromboembolic complications and silent ischemia. Secondarily, we compared the incidence of NIL among historical cohorts with guided and standard antiplatelet therapy.
methodsWe conducted a retrospective analysis of prospectively collected data from 171 patients who underwent carotid stenting in a single center between 2014 and 2023. Magnetic resonance imaging with diffusion-weighted images was performed before and after stenting. We evaluated NIL after the procedure and their dependence on patient demographics, degree of stenosis, instrumentation used, and antiplatelet therapy. The incidence of NIL was compared to three cohorts receiving more potent or guided antiplatelet therapy based on platelet function test (n = 689) and to seven cohorts receiving standard dual antiplatelet therapy with aspirin and clopidogrel (n = 2777), using the meta-analytical approach.
resultsNew ischemic lesions were found in 15.8% of patients (27/171). We recorded five ischemic strokes (2.9%). Most NIL were located in the ipsilateral middle cerebral artery basin (91%), but they also occurred contralaterally or in another basin. Stenosis length ≥ 15 mm (p = 0.012) was shown to be significantly associated with the development of NIL. The incidence of NIL in a center with guided antiplatelet therapy was distinctly lower compared to results of the studies with standard antiplatelet therapy, 15.8% vs. 28.3-51.3%.
conclusionGuided antiplatelet therapy in carotid stenting is safe and shows a lower incidence of new ischemic lesions on MR-DWI compared to results with standard antiplatelet therapy. In this study with guided antiplatelet therapy, NIL were only associated with greater stenosis length.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.